OBJECTIVE： To observe clinical efficacy and safety of Xinmailong injection combined with trimetazidine in the treatment of chronic heart failure of coronary heart disease （CHD）（Qi Yang deficiency ）. METHODS： A total of 80 patients with Qi Yang deficiency chronic heart failure of CHD were selected from our hospital during Jan. 2011-Dec. 2105 were divided into observation group and control group according to random number table， with 40 cases in each group. Both groups received routine treatment. Control group was additionally given Trimetazidine dihydrochloride tablets 20 mg， tid， for consecutive 6 months， on the basis of routine treatment. Observation group was additionally given Xinmailong injection 5 mg/kg added into 0.9％ Sodium chloride injection 500 mL， ivgtt， at speed of 30 drops/min， bid， medication interval＞6 h， for consecutive 5 days， on the basis of control group. Efficacies of cardiac function improvement， TCM symptom efficacies as well as LVEF before and after treatment were observed in 2 groups. The occurrence of ADR was compared between 2 groups. RESULTS： Total response rates of cardiac function and TCM symptom were 90.00％ and 95.00％ in observation group， which were significantly higher than 62.50％ and 55.00％ of control group， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in LVEF between 2 groups （P＞0.05）. After treatment， LEVF levels of 2 groups were increased significantly， and the observation group was significantly higher than the control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Xinmailong injection combined with trimetazidine in the treatment of Qi Yang deficiency chronic heart failure of CHD show significant therapeutic efficacy and improve LEVF level with good safety.